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Mice with human immune system components as
in vivo models for infections with human pathogens
Patrick C Ra¨mer, Obinna Chijioke, Sonja Meixlsperger, Carol S Leung and Christian Mu¨nz
Many pathogens relevant to human disease do not infect other animal species. Therefore, animal models that reconstitute or
harbor human tissues are explored as hosts for these. In this review, we will summarize recent advances to utilize mice with
human immune system components, reconstituted from hematopoietic progenitor cells in vivo. Such mice can be used to study
human pathogens that replicate in leukocytes. In addition to studying the replication of these pathogens, the reconstituted
human immune system components can also be analyzed for initiating immune responses and control against these infections.
Moreover, these new animal models of human infectious disease should replicate the reactivity of the human immune system to
vaccine candidates and, especially, the adjuvants contained in them, more faithfully.
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Mice are the preferred model species for immunological research.
However, during the 65 million years of divergent evolution, mouse
and man have accumulated many differences. Among all organs, most
of these differences fall into olfaction, reproduction and the immune
system.1 Many of the differences in the immune system relate to innate
immunity,2 which ensures the survival of the individual during the
first days after infection until the adaptive immune response can be
tailored to the specific needs of the particular challenge. As mice and
men encounter virtually non-overlapping groups of pathogens
because of their occupation of different ecological niches, these have
shaped the innate immune system of the two species quite differently.
These differences become especially important, because the innate
immune system initiates both rapid and adaptive immune responses,
and, therefore, human immune system reactivity toward vaccines,
pathogens and human disease-causing conditions in general are
difficult to model in mice. In these instances, the study of human
immune cells, ideally in vivo, would be preferable.
For this purpose investigators have transferred human immune cells
into immune compromised mice since the late 1980s in order to
overcome limitations of in vitro culture systems for human leuko-
cytes.3,4 However, only with the advent of the cytokine (interleukin
(IL)-2, 4, 7, 9, 15 and 21) receptor common gamma chain (gc) knock-
out into mice that already lacked T and B cells because of a scid
mutation or recombinase (Rag) deficiency, it has become possible to
engraft significant frequencies of cells from all human immune
compartments after transfer of fetal or neonatal human hematopoetic
progenitor cells (HPCs) into mice.5,6 In these mice, enhanced engraft-
ment is generally attributed to the lack of xenoreactivity mediated by
mouse natural killer (NK) cells, which seems to originate from the loss
of IL-15 signaling. Accordingly, non-obese diabetic (NOD)-scid gc/
or BALB/c Rag2/ gc/ mice are most often used for human
immune compartment reconstitution from transplanted HPCs, even
so some studies use parallel transplantation of human fetal liver, fetal
thymus and HPCs into NOD-scid mice (bone marrow, liver and
thymus (BLT)), alternatively (Figure 1).7 Mice transplanted with
human HPCs are able to reconstitute 40–60% of human CD45+
mononuclear cells in peripheral blood and spleen with sizable com-
partments of human B cells, T cells, NK cells, monocyte/macrophages
and dendritic cells (DCs) 3 month after HPC transfer (Table 1). In this
review, we will summarize studies on the immunocompetence of these
reconstituted human immune system components and discuss their
usefulness for studying infections by human pathogens as well as
vaccination approaches against these.
MODELING OF INNATE IMMUNE RESPONSES IN MICE WITH
RECONSTITUTED HUMAN IMMUNE SYSTEM COMPONENTS
Immune responses start with activation of the innate immune system,
which also harbors the most extensive genetic differences between
mouse and man. Therefore, the reconstitution and functional capacity
of innate human immune compartments in HPC-transplanted mice
needs to be analyzed in detail in order to determine if such recon-
stituted immune cells can serve as a surrogate for human innate
immune cells during studies on vaccination and infection.
Human NK cells
One of the most extensively studied cell population of the human
innate immune system in mice with reconstituted human immune
system components is the NK cell lineage. Initial studies mainly relied
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on in vivo application of human cytokines and growth factors in
various combinations to achieve sustained human NK cell develop-
ment or an expansion of these cells to detectable levels. In the
following, we will summarize these published data on development,
tissue distribution, frequency, phenotype and function of human NK
cells in reconstituted mice.
One of the first studies specifically addressing human NK cell
development in vivo used adult NOD-scid mice (8 weeks of age)
transplanted with CD34+ HPCs from cord blood. Without treatment,
no NK cells could be detected in this model. However, repetitive
treatment with various cytokine/growth factor combinations lead to a
transient increase in NK cells within the reconstituted mice lasting 3
weeks.8 Of note, all cytokine combinations that led to development of
human NK cells in vivo, contained IL-15 and flt3 ligand. Human NK
cell frequencies (frequency of CD56+ cells among human CD45+
lymphocytes) of 4–5% could be achieved in bone marrow and spleen,
and even higher percentages of 410% in peripheral blood. A
CD3+CD56+ NKT cell population was not induced on treatment, as
CD56+ cells were reported to be CD3. The phenotype of the NK cells
found in this study was mostly CD56dimKIR with CD16 expressed on
50–70% of all CD56+ NK cells. NK cells isolated from bone marrow of
these cytokine-treated mice produced IFN-g after additional in vitro
stimulation with IL-12 and IL-18, albeit at much lower frequencies
when compared with equally stimulated NK cells from human
peripheral blood. Interestingly, when in vitro expanded NK cells
isolated from reconstituted mice were adoptively transferred into
non-reconstituted NOD-scid recipients challenged with K562 tumor
cells, a significant decrease in tumor burden was observed (the K562
cell line is a major histocompatibility complex-I-deficient erythroleu-
kemic cell line). This study suggests that functional human NK cells
can be reconstituted in such mice, but require additional activation by
cytokines to maintain their functionality.
In contrast, when CD34+ HPCs isolated from human fetal liver
were transferred intrahepatically into newborn BALB/c Rag2/ gc /
instead of adult NOD-scid mice, another report could show multi-
lineage reconstitution of human immune cells (absolute number of
CD45+ cells in the spleen around 5106) and development of human
NK cells at low frequencies (0.3–1.5% of human lymphocytes) in all
organs analyzed.9 These human NK cells could be divided into the two
main subsets present in humans—CD56brightCD16KIR and
CD56dimCD16+KIR+ NK cells—with the former, irrespective of loca-
lization, representing the majority. This, however, is in contrast to the
distribution of these two subsets in man, in which there are remark-
able differences in subset ratio in different organs.10 Of interest, NK
cells almost devoid of CD56 expression could also be detected. These
cells were of NK cell origin, as they expressed the NK cell-specific
marker NKp4611 as well as NKG2D, CD94 and KIRs. The human NK
cell compartment in this model was functional. Interferon (IFN)-g
secretion after IL-12/-15/-18 stimulation ex vivo and degranulation in
response to co-culture with the NK cell susceptible erythroleukemia
cell line K562 in the presence of IL-15 could be detected. A direct
comparison with NK cell effector functions observed in human
samples was not provided. The investigators of this study furthermore
report an expansion of the human NK cell compartment shortly after
the repeated administration of IL-15 or IL-15/IL-15Ra hybrid mole-
cules. This happened at the expense of a skewing toward a more
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Figure 1 Main application areas for mice with reconstituted human immune system components. NOD-scid gc/ (NSG or NOG), NOD-scid with human fetal
liver and thymus organoid (BLT) and BALB/c Rag2/ gc/ mice with human immune system components, reconstituted from CD34+ HPCs can be used to
study human pathogen infection and immune control, vaccination with a special emphasis of adjuvant development for the human immune system, human
hematopoiesis and therapeutic interventions against human pathogens and malignancies.
Table 1 Human lymphocyte compartment reconstitution after 3–6 month of human fetal HPC transfer into mice
Mouse strain huCD45 (%) B cells T cells CD4+ T cells CD8+ T cells NK cells Reference
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) or
NOG (NODShi.Cg-Prkdcscid Il2rgtm1Sug/Jic)
40–60 40–60% of
hu-CD45+
30–50% of
hu-CD45+
60–75% of
hu-CD3+
25–40% of
hu-CD3+
3–5% of
hu-CD45+
Ishikawa et al.5;
Strowig et al.36
Rag2/ gc/ (C.Cg-Rag2tm1Fwa Il2rgtm1Sug/Jic or
Stock (H2d)-Rag2tm1Fwa Il2rgtm1Krf/Brn)
40–60 75–90% of
hu-CD45+
5–20% of
hu-CD45+
60–75% of
hu-CD3+
25–40% of
hu-CD3+
0.1–0.5% of
hu-CD45+
Traggiai et al.6
BLT (NOD.Cg-Prkdcscid with human fetal liver and
thymus organoid)
40–60 20% of
hu-CD45+
70% of
hu-CD45+
80% of
hu-CD3+
20% of
hu-CD3+
3–5% of
hu-CD45+
Melkus et al.7
Abbreviations: HPC, hematopoetic progenitor cell; NK, natural killer.
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differentiated CD56dimCD16+ phenotype, converting nearly all NK
cells to a CD16+ population with accompanying acquisition of KIR
expression. The duration of this increase in NK cell frequency after IL-
15 treatment was not reported. Along these lines, two other studies
compared NK cell reconstitution in BALB/c Rag2/ gc/ mice after
neonatal injection with cord blood CD34+ cells to reconstitution of
this compartment on HPC transfer into NOD-scid and C57BL/6
Rag2/ gc/mice.12,13 In the latter, CD45+ cell development did not
occur at all.12 In reconstituted BALB/c Rag2/ gc/ mice, the
highest frequencies of CD56+ cells were detected in lymph nodes,
but the majority of these cells also expressed the T-cell marker CD3.12
Further analysis of CD3CD56+ NK cells showed that NK cells in the
lymph node were virtually devoid of CD16 expression.13 In the spleen,
CD3CD56+ NK cells were CD16 whereas in the blood most NK
cells expressed CD16.12 Administration of an adenoviral vector-
encoding human IL-15 led to the expression of CD16 and KIRs on
almost all splenic NK cells and to a significant increase in the
frequency of CD56+ cells in the spleen to around 2% (% of CD45+
cells) 24 h after administration.13 These data suggest that significant
NK cell frequencies can only be achieved after HPC transfer into
BALB/c Rag2/ gc/ mice with additional supplementation with
IL-15 and that terminal differentiation of NK cells from
CD56brightCD16 NK cells can be achieved by the application of
this cytokine.
NOD-scid gc/ mice reconstituted with CD34+CD133+ cord
blood cells injected intracardially as newborns showed a higher
constitutive level of NK cells reconstitution. An expansion of NK
cells in blood, spleen, bone marrow, liver and lung similar to the above
mentioned was reported by Chen et al.14 after hydrodynamic injection
of plasmids encoding for human IL-15 and flt3 ligand. Frequencies of
CD3CD56+ NK cells of 410% (among human CD45+ cells) were
detected one week after gene delivery with a steady decline to still
elevated levels over an observational period of 30 days. Nine days after
hydrodynamic injection of IL-15 and flt3 ligand-encoding plasmids,
the absolute NK cell number per spleen was as high as 2106. Of note,
the administration of IL-15 and flt3 ligand-encoding plasmids led to
an overall increase in CD45+ cells content in spleen (above 20106)
and bone marrow with concomitant increases in DC, monocyte/
macrophage, B-cell and T-cell numbers. Apparently, the cytokine-
induced NK cell expansion did not occur at the expense of a loss of the
more immature CD16KIR phenotype, as the majority of NK cells
in bone marrow and spleen did not express CD16 or KIR molecules.
However, a direct comparison with the NK cell compartment in
reconstituted NSG mice without treatment was not conducted. NK
cells isolated from bone marrow and spleen of reconstituted NSG mice
treated with cytokine-encoding plasmids were able to specifically lyse
K562 tumor cells in vitro and produced IFN-g in the presence of
poly(I:C) and autologous human DCs. IFN-g levels were also
increased in sera of cytokine-treated mice after in vivo poly(I:C)
stimulation.
Moreover, hydrodynamic injection of DNA plasmids encoding
granulocyte-macrophage colony-stimulating factor, IL-4 and flt3
ligand in combination, as well as macrophage colony-stimulating
factor or IL-3 in combination with erythropoietin, all led to distinct
increase in the frequency of DCs (CD11c+CD209+), monocytes/
macrophages (CD14+) and human erythrocytes (CD235ab+).14
Recently, our group reported robust and stable overall NK cell
reconstitution in NOD-scid gc/ mice, neonatally reconstituted
with CD34+ human fetal liver HPCs by intrahepatic injection.15
This model allowed multi-lineage reconstitution with CD45+ frequen-
cies in peripheral blood of 60%. NK cell numbers in the spleen were
on average 3105 cells with frequencies ranging from 1.7 to 3.4%. In
peripheral blood of these mice, NK cells represented on average 5% of
human lymphocytes. NK cells were detected in all organs analyzed,
with the lowest frequency in the bone marrow. The analysis of the
human NK cell compartment demonstrated development of all NK
cell subsets present in human cord blood. Interestingly, a
CD3NKp46+CD56 NK cell subset was found that also exists in
human cord blood but is present only at very low frequencies in
human adult blood. This subset upregulated CD56 expression in vivo
when transferred into autologously reconstituted NSG mice as well as
in vitro in the presence of IL-15. In comparison with peripheral blood
mononuclear cell (PBMC)-derived NK cells, a decreased functional
capacity of NK cells from both mice with human immune system
components and cord blood was detected. This deficit was mainly
confined to the CD56dim and the NKp46+CD56 NK cell subsets.
Importantly, pre-activation of the human NK cell compartment from
reconstituted mice and from human cord blood with IL-15 in vitro or
poly(I:C) in vivo rendered these NK cells capable of secreting IFN-g
and degranulating in response to the target cell line K562. Levels of
activation were similar to human adult peripheral blood NK cells. In
addition, pre-activation with poly(I:C) in vivo led to enhanced killing
of major histocompatibility complex-class I-negative tumor cells
compared with parental major histocompatibility complex-class
I-expressing tumor cells. These studies demonstrate that functionally
competent NK cells can be reconstituted to half of the human
physiological frequencies after neonatal HPC transfer into newborn
NOD-scid gc/ mice. Cellular frequencies can be further expanded
by activation with IL-15.
In contrast, a recent report described adult NOD-scid gc/ mice
transplanted with mobilized CD34+ cells from human peripheral
blood donors and treated continuously with stabilized IL-7.16 The
developing NK cells in this system were reported to be functionally
inert, as they lacked cytotoxic activity against K562 target cells and did
not secrete IFN-g in bulk splenocyte cultures after phorbol 12-
myristate 13-acetate (PMA) and ionomycin stimulation. The pheno-
type of these cells was CD56bright, mostly CD16 and KIR. The
frequency of the NK cell compartment in this study did not exceed
5% in the organs analyzed. These data indicate that neonatal trans-
plantation with fetal HPCs might be superior in reconstituting
functional NK cell compartments in immune compromised mice.
Finally in BLT mice, which are NOD-scid mice transplanted as
adults with human thymus and liver organoids under their kidney
capsule followed by transfer of human fetal liver CD34+ cells, the
reconstitution of a human NK cell compartment was also independent
of further addition of cytokines and reached levels of 2% of CD45+
cells in peripheral blood 26 weeks after transplantation.7 A detailed
analysis of the NK cell phenotype and their functional capacity in this
model has, however, not been reported to date.
In summary, the high reconstitution efficiency in HPC injected
NOD-scid gc/ mice and BLT mice, compared with other mouse
models, and the presence therein of a functionally competent, but
resting NK cell compartment, suggests the preferential use of these
models in the analysis of the role for human NK cells in innate
immune responses to infection and cancer.
Human myeloid cells
Functional data on innate immune responses mediated by the myeloid
compartment of mouse models with reconstituted human immune
system compartments are scarce. This is due to the fact that DCs and
monocytes/macrophages are only found at low frequencies after
reconstitution in immune compromised mice (3% human myeloid
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cells among CD45+ leukocytes, and around 1% DCs, barely detectable
levels of granulocytes). One study reported the presence of CD15+
neutrophils in the bone marrow at a frequency of 4% at 8–12 weeks
after reconstitution of newborn NOD-scid gc/ mice.17 The same
group also characterized delayed-type hypersensitivity responses in
these mice after repeated challenge with trinitrobenzenesulfonate.
Administration of IL-7 before immunization augmented this response,
suggesting the existence of an intact innate and adaptive immune
system involving macrophages, DCs and T cells. When using keyhole
limpet hemocyanin as a delayed-type hypersensitivity response indu-
cing antigen in reconstituted NOD-scid gc/ mice, T cells and
macrophages infiltrated the site of injection, but no swelling could
be observed.18 In a model using parallel transplantation of liver,
thymus and HPC components into NOD-scid gc/ mice, delayed-
type hypersensitivity responses to tetanus toxoid and collagen V could
be elicited with swelling and an influx of human CD3+ T cells, CD68+
macrophages and mouse Ly6G+ leukocytes at the site of injection.19
Furthermore, administration of the superantigen toxic-shock-syn-
drome-toxin-1 into classical BLT mice led to a marked increase in
cytokines, an expansion of specific TCR Vb2+ T cells and the
upregulation of maturation and activation markers on CD11c+
DCs.7 Moreover, our group could prime antigen-specific T- and
B-cell responses in a vaccination study targeting human DCs in
NOD-scid gc/ mice with human immune system components.20
These studies suggest functionality of myeloid cells and DCs during
T-cell priming, delayed-type hypersensitivity and superantigen-driven
immune reactions. Mice reconstituted with human immune system
components might therefore be a useful tool to evaluate DC-targeted
vaccine candidates.
A recently described human DC subset with functional character-
istics similar to mouse CD8a+ DC and characterized by BDCA3
expression21–24 can also be found in reconstituted NOD-scid gc/
mice. The application of this or similar mouse models with human
immune system components offers the possibility to validate the
immunogenic potential of this DC subset in vivo. The highly transla-
tional setting of mice with human immune system components might
allow testing possible roles and benefits of these cell types in new
vaccination strategies.
ADAPTIVE IMMUNE RESPONSES TO INFECTIONS WITH
HUMAN PATHOGENS
In addition to studying human innate immune compartments, mice
with human immune system components offer the possibility to
analyze infections with pathogens displaying restricted tropism for
the human hematopoetic lineages, and the adaptive immune
responses they evoke. Furthermore, the introduction of human
leukocyte antigen (HLA) transgenes into the respective susceptible
mouse strains might even allow characterizing human immune
responses to pathogens with tropism for mouse somatic tissues.
Epstein–Barr virus
Epstein–Barr virus (EBV) is a g-herpesvirus that infects490% of the
human adult population worldwide. Although EBV can infect cotton-
top tamarins in experimental settings, humans are the only known
natural host for EBV. Primary EBV infection can remain asympto-
matic or—especially in adolescence and adulthood—can cause infec-
tious mononucleosis. Furthermore EBV infection is associated with
the development of various malignancies including Burkitt and
Hodgkin lymphoma, nasopharyngeal carcinoma and lymphoproli-
ferative diseases.25–27 EBV has the unique ability to immortalize B cells
and to transform them into lymphoblastoid cell lines. Like all human
herpes viruses, EBV establishes a lifelong latent infection, mainly of B
cells, within its host on primary infection.
All EBV-associated tumors express small nontranslated virally
encoded RNAs, including the EBV-encoded RNAs (EBERs) and a
subset of latent EBV proteins. The expression pattern of these latent
proteins differs between the various malignancies. Burkitt lymphoma,
for example, expresses only the nuclear antigen 1 of EBV (EBNA1) as
the sole latent gene product. This expression pattern is referred to as
latency I. In Hodgkin lymphoma and nasopharyngeal carcinoma, one
or both of the latent membrane proteins (LMPs), LMP1 and 2, are
expressed in addition (latency II). Only in tumors arising in immu-
nocompromised patients, like human immunodeficiency virus (HIV)-
infected individuals or transplant recipients, expression of all five
additional EBNA proteins 2, 3A, B, C and LP can be detected (latency
III). All three types of EBV latencies can also be found in healthy EBV
carriers and this EBV protein expression pattern seems to depend on
the differentiation stage of the infected B cells.28,29
Immune control of EBV is mainly mediated by T cells.30,31 As this
cellular subset of human lymphocytes poorly reconstitutes and sur-
vives in the xenogeneic mouse environment, experimental studies on
EBV immune control in mice have long been limited. As early as 1990,
it was shown that transfer of PBMC from healthy EBV carriers to scid
mice leads to the development of tumors that in many aspects
resemble EBV-driven lymphoproliferative disease (LPD).32 However,
the poor survival of human T cells within the transferred PBMCs did
not allow any assessment of T-cell-mediated immune control. Never-
theless, autologous ex vivo expanded EBV-specific cytotoxic T lym-
phocytes (CTLs) did home to sites of tumor formation in this model
and specifically killed infected tumor cells.33 The first mouse strain
allowing direct EBV infection in mice after reconstitution with human
immune cells was the NOD-scid mouse.34 On injection of HPCs,
human B cells develop in these animals and can be infected with EBV
by injection of virus containing culture supernatants. At 4–6 weeks
after infection, mice showed disseminated LPD and high titers of viral
DNA could be detected in peripheral blood. Like most EBV-driven
tumors found to date in mice with human immune system compo-
nents, these tumors expressed EBERs, LMP1 and EBNA2, thereby
indicating latency III. Residual mouse NK cell activity in NOD-scid
mice, however, limits the development of human T cells and thereby
hampers attempts to analyze T-cell-mediated immune control.
As discussed above, the additional knockout of the common
g-chain in NOD-scid as well as in BALB/c Rag2/ mice minimizes
residual murine NK cell activity and thus allows robust T-cell devel-
opment after reconstitution with human HSC. In a seminal publica-
tion Traggiai et al.6 could show stable human T-cell homeostasis in
BALB/c Rag2/ gc/ mice reconstituted with human HPCs. These
T cells expand upon EBV infection. As similar to primary EBV
infection in humans, the vast majority of expanding T cells are
CD8+ T cells, this induces an inversion of the CD4+ T cells/CD8+
T cells ratio in the spleen. T cells isolated from infected mice produce
IFN-g when stimulated with autologous lymphoblastoid cell lines,
thereby proving in vivo T-cell priming. Similar findings were also
reported using BLT and NOD-scid gc/ mice.7,35 The latter mouse
strain has been used by our group and others to further characterize
EBV infection and immune control in reconstituted mice. EBV
infection in these mice shows a dose-dependent effect. Low-dose
infection (104 Raji infectious units) leads to T-cell reactivities against
lymphoblastoid cell lines and asymptomatic EBV persistence. In
contrast, intermediate- and high-dose EBV infection (105 and 106
RIU (Raji infectious units), respectively) results in a stronger expan-
sion of EBV-specific T cells and especially high-dose infection even
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results in EBV-driven tumor formation. Expanded T cells furthermore
show direct cytotoxicity against autologous lymphoblastoid cell line
and their EBV-epitope specificity could be identified by peptide
stimulation. Among expanded T cells, high frequencies of CD45RO+
and HLA-DR+ cells can be detected, indicating an activated, memory
T-cell-like phenotype.35,36 Research from our group demonstrated
that the observed priming of EBV-specific T cells is of protective
value.36 Depletion of human T cells before EBV infection resulted in
the development of disseminated LPD and higher viral DNA loads in
the spleen of infected animals at early time points after infection. Of
note, CD4+ T-cell depletion alone as well as sole CD8+ T-cell depletion
lead to a significant increase in viral DNA load. Yajima et al.37 who
reported a more rapid onset of LPD and a shorter lifespan in
reconstituted EBV-infected mice after T-cell depletion, confirmed
the protective value of T cells in this system.
However, human T cells in reconstituted NOD-scid gc/ and
Rag2/ gc/ mice are selected under suboptimal conditions on
mouse thymic-epithelial cells and human bone marrow-derived cells
in the murine thymus. This unphysiological selection process, which
includes selection on human major histocompatibility complex as well
as on mouse H2 molecules, seems to result in different affinities and
specificities than T cells selection in an all-human setting. This might
explain why the detected T-cell specificities were mostly directed
against subdominant EBV epitopes. Such limitations can be overcome
by the introduction of human HLA transgenes into the mouse
genome. After insertion of a human HLA-A2 heavy chain transgene
into NOD-scid gc/ mice (NSG-A2 mice), immuno-dominant pep-
tide specificities against EBV lytic and latent antigens can be detected
at relatively high frequencies.36,38
In summary, mice reconstituted with human immune system
components model many aspects of EBV infection and immune
control that can also be found in humans. EBV infection of such
mice leads to T-cell expansion with an inversion of the CD4+/CD8+ T
cell ratio and a predominance of activated memory-like T cells. It
primes protective antiviral T-cell responses in a dose-dependent
manner and primed T cells recognize EBV-derived epitopes that can
also be found in human EBV carriers. At higher viral doses, EBV can
cause LPD formation and by their expression of latent EBV proteins,
these LPDs resemble tumors that are normally found in immuno-
compromised patients.
For the future, mouse models with reconstituted human immune
system components offer many interesting possibilities for research on
EBV biology and immune control. Additional latency patterns asso-
ciated with different EBV-associated malignancies might be accessible
in these mice under certain infection conditions.39 If the exact
requirements for these could be further defined, immune control of
EBV malignancies associated with these ‘non-type III’ latencies
including Hodgkin disease and Burkitt’s lmphoma could be studied
in greater detail.
Mice with reconstituted human immune system components could
furthermore serve as a model for preclinical drug testing. Until now,
specific drug treatment of EBV-associated diseases relies mainly on
inhibitors of viral DNA polymerases like Aciclovir. DNA polymerase
inhibitors are effectively reducing viral DNA synthesis during lytic
replication of EBV, but they fail to effectively target EBV in latently
infected cells. To circumvent this problem, one arm of current research
focuses on the development of small molecules targeting latent EBV
proteins like EBNA1 and inhibiting their function.40 Mice with human
immune system components can help to test safety and efficacy of
these and other new drugs before they enter tests in primates or even
humans.
In addition, such models might allow for the first time the
assessment of the in vivo biology and the immune control of
genetically modified EBV strains. Various modified EBV strains
derived from artificial bacterial chromosomes have been developed
over the last decade. So far the effect of targeted mutation or deletion
of specific EBV genes could only be addressed in vitro. How would, for
example, modifications of the viral lytic cycle by deletion of the main
lytic transactivator BZLF-141 affect virus persistence and T-cell prim-
ing? Or how would the loss of immuodominant proteins like
EBNA3B42 affect tumor development and immune surveillance in
vivo? These and other questions could not be addressed so far. Mice
with human immune system components will help to find answers to
some of those questions and will hopefully broaden our understand-
ing of the complex interaction EBV has with the human body.
Dengue virus
The four serotypes of dengue virus (DENV) belong to the family of
Flaviviridae, which are small enveloped RNA viruses. They are
transmitted by mosquito bites and global incidence has increased
drastically over the past decades, especially in Asia. Infection can lead
to a flu-like disease called dengue fever. Symptoms range from mild-
to-severe and include fever, rash, headache, nausea and vomiting as
well as muscle and joint pain. The cellular basis and contribution of
the host’s immune system to disease are not understood in detail. In
some cases and especially after secondary infection with another
serotype, patients develop dengue hemorrhagic fever with thrombo-
cytopenia and plasma leakage, which can be fatal. To date, there is no
specific antiviral treatment or licensed vaccine available partly because
of the lack of an appropriate animal model. Non-human primates
support productive infection, but they do not show symptoms of
dengue fever or dengue hemorrhagic fever. Several mouse models have
been used to study aspects of DENV infection in the past, however, the
relevance of the results for the human setting is limited. Infectious
doses were un-physiologically high or the mice were not fully
immunocompetent. Furthermore, mouse-brain-adapted virus strains
were used or virus was injected into the central nervous system
directly. To overcome some of these limitations, Bente et al.43 infected
NOD-scid mice reconstituted with CD34+ cord blood cells with
DENV serotype 2 subcutaneously to mimic mosquito bites. Mice
developed symptoms associated with dengue fever like an increase
in body temperature, rash and thrombocytopenia. Mota and
Rico-Hesse44 used reconstituted NOD-scid gc/ mice to compare
the severity of these symptoms induced by different strains of DENV
serotype 2 after a low dose, subcutaneous injection. In accordance
with experiments in human target cells, a Southeast Asian strain was
the most virulent one in this mouse model. It was also the only strain
that induced the production of DENV-specific antibodies. Also
reconstituted Rag2/ gc/ mice support DENV infection. Similarly,
they develop fever, but unlike reconstituted NOD-scid gc/ mice,
they do not display signs of rash or hemorrhage after combined
intraperitoneal and subcutaneous DENV injection. They did, however,
generate DENV-specific immunoglobulin (Ig)M and IgG antibodies,
which in part had neutralizing capacity.45 It is also possible to generate
a DENV-specific T-cell response in reconstituted mice. When Jaiswal
et al.46 infected HLA-A2 transgenic NOD-scid gc/ mice reconsti-
tuted with HLA-A2-positive HPCs, they detected T cells that secreted
IFN-g, IL-2 or tumor necrosis factor-a after restimulation with a
DENV peptide pool.
In conclusion, there are differences in symptoms and the time
period of the immune response to DENV in the reports discussed
above, which are most likely because of the use of different mouse
Pathogen infection of humanized mice
PC Ra¨mer et al
5
Immunology and Cell Biology
models of human immune components reconstitution. Nonetheless,
reconstituted mice seem to emerge as a good model to study the
pathogenesis of DENVand should help discover therapeutic as well as
preventive strategies.
HIV
Despite all efforts, infection with HIV and the resulting immunode-
ficiency are still a major threat to global health. In 2008, 2.7 million
people were newly infected with HIV, with a total of 33.4 million
people being HIV-positive worldwide (World Health Organization).
The most common form of transmission is by sexual intercourse.
In the acute phase of infection, HIV levels in plasma peak. Subse-
quently, HIV levels drop, most likely because of a CD8+ T-cell
response that eliminates infected cells. The major target cells are
CD4+ T cells, but also monocytes, macrophages and DCs can be
infected. In the latent phase of infection, the human immune system
controls viral infection, resulting in low viral levels in plasma. Over
time, CD4+ T-cell levels decrease causing the immune system to lose
functionality. This gives rise to opportunistic infections and cancer
development that eventually will cause death. Combined antiretroviral
therapy delays disease progression, but there is no cure or vaccine
available to date. Major problems pose the integration of the viral
DNA into the host DNA for long-term viral persistence and the high
mutation rate of the virus facilitating immune evasion. Furthermore,
we lack a suitable animal model to study HIV infection and to test
new antiviral therapeutics and vaccines. Experiments in chimpanzees,
macaques, cats, rats and mice have allowed insights into several
aspects of HIV biology.47 However, HIV pathogenesis in these models
as well as the resulting immune response differs from human infec-
tion. To overcome these problems, several mouse models with
reconstituted human immune system components have been tested
to date. Early experiments were carried out in scid mice with a human
fetal thymus and liver transplant (SCID-hu thy/liv mice). HIV isolates
could infect T cells and thymocytes in the engrafted human thymus of
these mice and infection lead to T-cell depletion.48–51 Therefore, this
model allows in vivo drug testing and the study of viral cytopatho-
genicity. The major limitation is the lack of a complete immune
system with circulating lymphocytes and human antigen-presenting
cells. In contrast, more cellular compartments can engraft in scid mice,
when transplanted with human peripheral blood mononuclear cells
(SCID-hu-PBL). Nevertheless, this model mainly allows the analysis of
the acute phase of infection and the evaluation of antiretroviral
therapy, as also here CD4+ T-cell depletion is rapid and T cells are
not replenished.52,53
In the past few years, several mouse models were tested for HIV
infection that have the capacity to renew their human T-cell compart-
ment after reconstitution of human immune system components from
HPCs, namely Rag2/ gc/, NOD-scid gc/ and BLT mice. All
models support viral infection with viremia in the plasma, show
dissemination of the virus to various organs and exhibit CD4+ T-cell
depletion.54–61 Most importantly, all these reconstituted mice mount
at least weak immune responses to HIV. Several groups detected a
humoral immune response, however, at low frequencies. For example,
Baenziger et al.54 reported one IgG producing mouse after HIV
infection in reconstituted Rag2/ gc/ mice. In another study, 3
out of 14 reconstituted NOD-scid gc/ mice produced antibodies
that were specific for env gp120 or gag p24.57 In the same mouse
background, Sato et al.62 found IgG in seven out of seven infected
mice (data shown for two), which were in part specific for gp41. One
reason for a higher IgG frequency in this study might be the long
period of time between infection and analysis. Also the majority of
infected BLT mice generated HIV-specific antibodies with epitopes
including gag, nef, pol and env after prolonged time periods of
infection.63 In addition to a late time point for analysis, having a
human thymus in BLT mice might allow the generation of more
potent T helper cells and thereby more frequent antibody responses.
With respect to the T-cell compartment and cellular immune
responses to HIV in reconstituted mice, the characteristic feature in
all reported studies is the loss of CD4+ T cells. For example, infection
with CXCR4-tropic HIV induced fast depletion of both naı¨ve and
memory T cells. In contrast, CD45RO+ effector memory T cells were
preferentially and gradually lost in CCR5-tropic HIV-infected mice.64
Furthermore, CD25+, FOXP3+-positive regulatory T cells are also
preferentially depleted by HIV infection in Rag2/ gc/ mice.65
On the other hand, HIV infection induces proliferation of CD8+ T
cells. At least in reconstituted NOD-scid gc/ mice, this could mainly
be accounted for by an increase in CD45RACD8+ memory T cells.62
In BLT mice, Sun et al.60 reported activated, CCR5+, as well as
granzyme and perforin-positive CD8+ T cells in lymph nodes after
HIV infection. Accordingly, Brainard et al.63 found a significant
increase in activated CD69 and HLA-DR-positive CD8+ T cells as
well as perforin-positive CD8+ T cells in HIV-infected BLT mice in
comparison with uninfected mice. In addition, they detected HIV-
specific T-cell responses 9 weeks after infection. CD4+ as well as CD8+
T cells produced IFN-g after ex vivo peptide restimulation.63 Interest-
ingly, gag and nef were the most frequently recognized T-cell antigens
in these mice as is the case in human HIV-infected patients. Despite
this robust immune response, also the BLTmice of this study did not
show decreased viral load after T-cell priming. One possible explana-
tion might be emerging T-cell exhaustion. As in chronic human
infection, HIV lead to an increase in frequency and expression levels
of PD-1 on CD4+ and CD8+ T cells in BLT mice. Furthermore, there
was a positive correlation between the percentage of PD-1-positive
cells and plasma viremia,63 which supports this hypothesis.
In line with the findings in BLTmice, reconstituted NOD-scid gc/
mice mount a strong HIV-specific cellular immune response. After
restimulation with a gag-derived peptide pool, CD4+ and CD8+ T cells
of most infected mice produced IFN-g and a subset of these cells was
also producing IL-2.66 The importance of the CD8+ T-cell response
was underscored by depletion experiments. Although administration
of CD8-depleting antibody several weeks after infection only had a
mild effect on viral load, viremia was significantly increased when
CD8+ T cells were depleted 2 weeks after infection.66
In all studies mentioned above, mice were infected with CXCR4-
and/or CCR5-tropic HIV by intraperitoneal injection. For a more
physiological way of exposure, Sun et al.60 infected BLT mice intrar-
ectally after abrasion of the rectal epithelium. Like intraperitoneal
injection, this lead to viral spread throughout the body and CD4+
T-cell depletion. The same can be achieved by intravaginal infection.67
Of note, pre-exposure prophylaxis with antiretroviral drugs prevented
vaginal HIV transmission. Rectal and vaginal transmission has also
been shown for Rag2/gc/ mice,55 but could not be reproduced by
another group possibly because of very low overall levels of recon-
stitution in this particular mouse background.68
Taken together, the newer mouse models with reconstituted human
immune system components recapitulate various aspects of HIV
infection in humans and even allow the study of long-term chronic
HIV infection.69 Better immune control might be achieved after
improved reconstitution in transgenically modified mice expressing
human HLA molecules or cytokines. Of course, one has to keep in
mind that various cofactors have a role in acquired immune deficiency
syndrome progression. Only few studies tried to address an impaired
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integrity of the intestinal barrier as seen in patients.70 Additionally,
coinfection with other pathogens will need to be studied more
intensively.71–73 Nonetheless, mice with human immune system com-
ponents are useful tools to test antiretroviral therapeutics and possibly
vaccines.47,67,74–77 However, it will be important to test compounds in
mice and patients side by side to determine whether results in mice
with human immune system components can be extrapolated to the
human setting.
VACCINATION IN MICE WITH HUMAN IMMUNE SYSTEM
COMPONENTS
Mice with reconstituted human immune components can serve as
preclinical surrogate models to investigate the pathogenesis of viral
infections and other human diseases. These models are new tools in
the development of effective and affordable vaccines and therapeutics.
Vaccination against EBV-associated diseases
Although over the past years different therapeutic vaccination
approaches against EBV-positive malignancies were able to lead to
an expansion of T cells specific for viral antigens, no study so far has
proven to be clinically effective against Hodgkin’s lymphoma and
nasopharyngeal carcinoma.78,79 In a nasopharyngeal carcinoma trial
using ex vivo generated DCs pulsed with peptides derived from EBV
proteins, expansion of EBV-specific CD8+ cytotoxic T cells could be
detected. Clinically, however, no remission or slowing of tumor
growth could be observed.78 These data indicate that it is crucial to
test whether the primary T-cell responses elicited in vitro will confer
protection against virally transformed cells and tumors in vivo.
As EBV-specific T-cell responses limit viremia and tumor formation
during infection in reconstituted NOD-scid gc/ mice,36,37 this
particular mouse model seems suitable to test vaccine candidates
that aim to induce protective T-cell responses. Along these lines, we
tested vaccination with an EBNA1 fusion antibody targeting the
endocytic DEC-205 receptor on human DCs together with the
application of a TLR3/mda5 agonist as adjuvant in such reconstituted
mice. In response, they elicited EBNA1-specifc T-cell response as well
as anti-EBNA1 antibodies.20 However, the observed levels of T-cell
reactivity in most vaccinated mice were 10-fold lower than the levels of
reactivity observed during intermediate-dose EBV infection.36 There-
fore, these encouraging results will need further improvement before
vaccinated mice can be challenged with high-dose EBV infections.
Such improvements might include selection of more efficient adjuvant
formulations to boost DC maturation for more efficient T-cell
priming after antigen has been targeted to them.
Vaccination against HIV
Lots of attempts to generate a vaccine against HIV-1 have failed
despite more than 20 years of effort. The virus envelope has evolved to
evade neutralizing antibodies and continuous mutations of the virus
are enabling it to evade anti-HIV T-cell responses.80 Two highly
publicized HIV vaccine trials were prematurely terminated because
of a high frequency of sero-conversions among vaccine recipients,
indicating non-effectiveness of the vaccine.81 With these disappointing
results, there has been increased interest in rodent models with human
immune system components for HIV infection in order to test
preclinical vaccine candidates. Earlier studies using SCID-hu-PBL
mouse models showed that high doses of the neutralizing human
monoclonal antibody IgG1b12 can block viral entry and thereby can
protect the host from developing high plasma viremia.82,83 However,
the transferred PBMCs in this mouse model did not sustain T-cell
reconstitution and, therefore, HIV-1 infection. Over time, such mice
furthermore suffer from a severe (xeno-) graft versus host disease,
because of high xenoreacitivy of the transplanted human PBMCs
against the murine host’s cells. Rag2/ gc/, NOD-scid gc/ and
BLT mice, on the contrary, support long-lasting and robust in situ
development of human hematopoietic cells, relevant to HIV infec-
tion.54,57,59 However, the immune responses in these mice are still
suboptimal with both humoral and adaptive HIV-specific immune
responses only developing after several months of HIV infection.
Nevertheless, the observation that CD8+ T-cell response at least
partially control viremia in reconstituted NOD-scid gc/ mice,66
might offer the opportunity to test vaccine candidates in at least
this particular mouse background in the future.
Vaccination against other pathogens
Apart from testing potential vaccine candidates against EBV and HIV,
mice reconstituted with human immune system components have also
been employed to test reactivities elicited by established vaccines or
new vaccine candidates against other pathogens. Mice with human
immune system components were used to test vaccines against severe
acute respiratory syndrome-associated corona virus. Okada et al.84,85
transfused PBMCs from healthy human volunteers into NOD-scid
gc/ mice and immunized these mice with complementary DNA
constructs encoding the structural antigens of the virus. After three
immunizations, the candidate vaccine could induce a human neutra-
lizing antibody response and a modest cytotoxic T-cell response
specific to the virus. However, the xenorecognition of the mouse
host by the transferred PBMCs could augment adjuvant activity of the
vaccine. This activation would not be observed during vaccination of
humans.
Rapid allo- and xenorecognition is mostly mediated by human
memory T cells. To circumvent this reactivities, cord blood mono-
nuclear cells, which almost exclusively consist of naı¨ve T cells, have
been used to engraft NOD-scid mice in other studies. This model was
for example used to test an adenoviral cancer vaccine to human
carcino–embryonic antigen. Camacho et al.86 demonstrated that
engrafted human lymphocytes responded to the cancer vaccine by
producing IFN-g when the restimulated in vitro with carcino–embryo-
nic antigen peptides. However, the protective value of the induced
T-cell responses was not explored and even naı¨ve, but fully educated
human T cells might raise xenoreactive immune responses toward
their mouse host over time, thereby at least in part contributing to the
observed T cells activation. In newborn mice transplanted with human
HPCs, developing human lymphocytes are tolerized against mouse
tissue because of their selection in the mouse thymus. Therefore, these
models might be more favorable for vaccine studies.
Traggiai et al.6 vaccinated reconstituted BALB/c Rag2/ gc/mice
with tetanus toxoid and this immunization induced measurable anti-
tetanus toxoid IgG antibodies. However, the detected antibody levels
were significantly lower than those achieved in human adults.
Furthermore, a recent study showed that NOD-scid b2m/ mice
engrafted with adult human CD34+ HPCs and further reconstituted
with human T cells, can mount specific immune responses against
influenza virus vaccines.87 Influenza matrix protein 1-specific CD8+
T cells were expanded in mice vaccinated with inactivated trivalent
influenza virus vaccine. The expansion of these antigen-specific CD8+
T cells required reconstitution of the human myeloid compartment.
Nevertheless, the protective value of this vaccine response against
influenza virus infection was not investigated in this study.
Taken together, mice with reconstituted human immune system
components are now able to model certain aspects of infections
with human pathogens and the specific immune control of these.
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However, immunity following vaccinations remains suboptimal and
the potency of novel vaccine candidates, especially to trigger cell-
mediated immune responses needs to be further improved, before
the protective value of these vaccine candidates can be evaluated by
subsequent infection with human pathogens.
CONCLUSIONS
With the advent of new mouse strains showing improved tolerance
toward human immune system component reconstitution in vivo,
most human immune compartments can now be reconstituted for
prolonged periods of time in vivo. These mouse models can serve as
tools to study infection and to some extent immune control of human
pathogens in vivo. Although innate immune responses and T-cell
responses can probably be modeled fairly well, the lack of steady-state
germinal center formation and the associated defect in isotype switch-
ing and affinity maturation of humoral human immune responses,
will probably limit the usefulness of these new models against
pathogens that require antibody-mediated neutralization for immune
control. However, these models might be rather suitable to study
pathogens like EBV that are primarily controlled by T-cell-mediated
immunity. Furthermore, vaccine development that aims to primarily
evaluate antigen plus adjuvant candidates for improved T-cell immu-
nity might be advanced in these mice. As pathogen-associated
molecular pattern recognition differs between mouse and man and
strongly affects adjuvant recognition during vaccination, vaccination
studies might especially benefit from these new models.
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